Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Nadda underlined that India’s policy framework is aligned with this transformation
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Subscribe To Our Newsletter & Stay Updated